valu usd unless otherwis note
three main question continu
see upsid rais target
view first quarter result show resili guidanc
unchang think focu
earn power come three thing
core busi deliv core product upsid ii
aesthet busi deliv v-shape recoveri iii earlier
captur synergi opportun reiter op target
core busi deliv upsid over-conserv
forecast busi prove resili
expect good part strength skyrizi recent
survey link rinvoq overal busi held well first take
 link rais stand-alone ep flow
new pro-forma ep
point ramp skyrizi rinvoq valid
humira market share resili imbruvica growth robust
humira remain question biosimilar entri known
growth outlook remain debat point one
increasingli look opportun multipl re-rat compani
strateg deliv visibl growth period
aesthet busi deliv v-shape recoveri
major focu call two thing think
relat derm/aesthet close larg shut access near-
term ii anticip econom sensit recess ad
uncertainti given cash pay dynam long histori
busi view two-fold assumpt offic re-
open think wareh effect patient look
pursu treatment catch-up ii econom recess busi
histor hit hard ultim bounc back quickli
would point back report deep dive
bring pro-forma forecast outlook set-up detail come
financi crisi saw meaning doubl digit rebound botox
aesthet
earlier aggress cost synergi opportun
target cost synergi billion year accret
first full year peak cost synergi
oper expens easier cut delay deal close
given abbv/agn time prepar word would question
whether see year upsid see pro-forma model
exhibit perspect estim million cost synergi
ep said differ roughli ep come
synergi potenti pull forward
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
bloomberg capit market estim upside/downside/target
base case see price target impli price-to-earnings
pro-forma ep
assum may deal close allergan
specif addit accret built estim
expect continu annual busi develop
strong uptak key growth product skyrizi
assum slowdown
econom downturn
upsid case scenario see price target impli
price-to-earnings pro-forma ep
invest thesi base view
abb gener double-digit near-term growth growth
back catch-up strength core
franchis continu long-term question post
us humira loss exclus loe see dividend
support synergy-driven support next three
year thesi base follow key point
support outperformr
see greater impact street around
expect catch-up signific
support robust growth biggest concern around
aesthet franchis compris
pro-forma revenu follow immunolog slow-down
check suggest bounc back meaning
long-term growth stori still unclear valuat
price littl humira goe biosimilar
see pressur out-year earn time
next year balanc sheet focu
reposit long-term growth also see option
around spin ipo acquir medic aesthet
believ highest dividend lowest
valuat could support share see upsid
potenti offens post recoveri
trade close histor low see cash flow support
current sector-high dividend help support
share anticip recoveri
faster uptak key growth product skyrizi
assum deal close allergan addit
accret built estim
lower humira eros follow us loss exclus
quicker clear relat pandem
potenti catalyst close allergan acquisit may
sever data read focu rinvoq ph data
atop derm skyrizi motiv data
cd induct bi voltaire-x interchang studi
read-out biosimilar humira head-to-head calquence/
imbruvica data r/r cll
risk thesi delay close allergan deal
competit risk particularli around hem-onc franchis
botox slower uptak key grower greater
expect impact
downsid case scenario see price target
impli price-to-earnings downsid pro-forma ep
sluggish uptak key growth product skyrizi
assum prolong deal closur allergan and/or
stringent ftc divestitur requir expect
aggress humira eros follow us loss
exclus expect
greater impact expect
forma incom stand-alon modellegaci stand-alon modelless net product zenpep contributiongross profit cost synergi year oper incom expens foreign exchang incom expens interest expens incom tax tax earn ep share share per rate legaci legaci net profit analysi share per exhibit
 incom guid appr op growth product profit guid approach guid guid salesoper incom guid sale expens guid billionnet foreign exchang incom expens interest expens incom tax tax guid adjust tax rate earn ep guid share share guid flatdividend per increas announc yield price dividend yield assum annual increasesebitda guid approach guid guid salesoper guid sale guid profit analysi guid appr op growth share per inc
price target base equal ev/ebitda price-to-earnings estim reflect
close allergan acquisit use multipl respect
reflect meaning discount histor industri averag adjust us loss
exclus humira impli return price target support outperform
risk rate price target
risk rate price target includ limit tail valu risk
humira still meaning contributor combin compani acquisit risk work
close integr allergan transact largest deal histori
regulatory/polit risk broadli applic sector particularli around pricing/
global biopharmaceut compani base chicago il spun
abbott becam independ publicly-trad compani compani
track record acquisit pharmacycl stemcentrx
announc acquisit allergan expect close upon
close allergan transact combin compani focus immunolog
hematolog oncolog medic aesthet neurosci franchis
